NCT05231603View on ClinicalTrials.gov

Ivermectin for Post Exposure Prophylaxis of Covid-19

PHASE3TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

May 31, 2022

Study Completion Date

October 11, 2022

Conditions
COVID-19
Interventions
DRUG

Ivermectin

0.4 mg/kg/day-maximum dose is 24 mg.

OTHER

Placebo

Similar to drug in term of tablets

Trial Locations (10)

13700

KK Seberang Jaya, Butterworth

30450

KK Greentown, Ipoh

31050

KK Karai, Kuala Kangsar

32400

KK Ayer Tawar, Sitiawan

34000

KK Simpang, Taiping

34300

KK Bagan Serai, Bagan Serai

35000

KK Tapah, Tapah

35900

KK Tanjung Malim, Slim River

08000

KK Bandar Sg Petani, Sungai Petani

01000

KK Kangar, Kangar

Sponsors
All Listed Sponsors
collaborator

Hovid Berhad

INDUSTRY

lead

Clinical Research Centre, Malaysia

OTHER